Abbott has agreed with the FDA to resume production at its infant formula plant in Sturgis, Michigan. Once the FDA confirms that the initial requirements for production have been met, Abbott will be able to resume production within two weeks. Products will not be available for sale until six to eight weeks after production has resumed.